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Introduction
Treatment options for patients with metastatic colon 
and rectal cancer (CRC) that have progressed following 
standard first and second lines of treatment are limited. 
The approvals of regorafenib and TAS-102 filled a void; 
however, results are disappointing for most patients (1,2). 
Patients with microsatellite unstable tumors may benefit 
from immunotherapy, however this represents a minority 
of cases (3). Novel approaches are needed for patients with 
refractory CRC (4).
Pre-clinical studies have demonstrated that cytokine 
mediated inflammation plays a role in carcinogenesis 
and prognosis in CRC (5). Interleukin-6 (IL-6) is an 
inflammatory cytokine that binds to receptors that mediate 
signaling by the JAK/STAT pathway. Phosphorylated 
STAT3 is a transcription promoter of genes associated with 
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cell survival, proliferation, angiogenesis, metastasis, cell 
adhesion, and inflammation (6). Inhibiting this pathway 
in both CRC cell lines and mouse CRC xenograft models 
resulted in apoptosis and tumor responses (7). 
Pacritinib is an orally administered multi-kinase 
inhibitor with potent JAK and FLT3 inhibition. It has been 
extensively evaluated in early phase trials in hematologic 
malignancies  including myelofibrosis ,  AML, and 
myeloproliferative neoplasms and shown to have a favorable 
safety profile (8). 
This phase II single arm, single institutional trial 
sought to examine the effect of JAK/STAT inhibition with 
pacritinib in patients with refractory colorectal cancers. 
Methods
Eligibility criteria
Eligible patients had metastatic CRC refractory or 
intolerant to at least two lines of chemotherapy and 
evaluable or measurable disease by RECIST version 1.1, 
and Eastern Cooperative Oncology Group performance 
status of 0 or 1. Patients also had to be ≥18 years old with 
adequate bone marrow, hepatic and renal function as well as 
life expectancy of at least 3 months. Key exclusion criteria 
included prior therapy with JAK or FLT3 inhibitors, 
chemotherapy or targeted agent within 2 weeks of initiating 
study drug, known brain metastasis, or uncontrolled 
intercurrent illness. The protocol (ClinicalTrials.gov 
identifier: NCT02277093) was approved by the institutional 
review board of Washington University (IRB00009237) 
and written informed consent was obtained for all patients 
before performing study-related procedures.
Drug administration and study design
Pacritinib was administered orally continuously on a 
28-day cycle at a dose of 200 mg twice daily. This dose 
was determined based on published phase one studies 
of pacritinib in patients with myeloid malignancies and 
myeloproliferative neoplasms (9). Patients underwent a 
baseline history and physical examination, ECG including 
QTc measurement, CT chest/abdomen/pelvis within 4 
weeks, and CBC, CMP, and magnesium measurement. 
While on treatment patients were monitored with weekly 
blood work and every other week office visits and ECG 
with QTc measurement. Response assessment was by CT 
scans every two cycles or sooner if deemed necessary by the 
treating physician.
Correlative studies
Planned correlative studies included measurement of 
erythrocyte sedimentation rate and C-reactive protein. 
Serum IL-6 and interleukin-8 (IL-8) levels were also 
measured at baseline and monthly on treatment.
Statistical considerations
We proposed a meaningful primary outcome favoring 
continued development of pacritinib in refractory CRC was 
a median PFS of 4 months. The planned sample size of 38 
patients would have given the study ≥0.90 power to identify 
an increase in median PFS from 1.7 to 4.0 months.
Results
Patient population
Eleven patients with refractory metastatic colon or rectal 
cancer were enrolled between September 2015 and February 
2016. Patient characteristics are presented in Table 1. 
Median age was 63 years. All patients had been treated with 
FOLFOX and FOLFIRI. The three RAS wildtype patients 
had received panitumumab and nine patients had received 
bevacizumab. Five patients had participated in other clinical 
trials. The baseline median CRP level was 12.1 mg/L with a 
range of 2.1 to 147 mg/L.
Adverse events
All patients experienced at least grade 1 or 2 adverse events. 
The most common being nausea (5 patients, 50%) followed 
by abdominal cramping and constipation. Five patients 
experienced a total of 14 unique grade 3 adverse events. 
There were no grade 4 or 5 events on study (Table 2). 
Correlative studies
CRP and interleukin concentrations at baseline and 
after the first cycle were available for 7 and 9 patients 
respectively. Interleukin 6 and 8 plasma levels were 
measured by Luminex high sensitivity multiplex assay. The 
patient with stable disease by RECIST at 2 months had 
the lowest baseline CRP of 2.1 mg/L. The patient with 
the highest CRP on study, 147 mg/L had a large burden of 
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liver metastasis and an elevated total bilirubin not related 
to pacritinib. IL-6 and IL-8 levels increased in all patients 
after 1 month of treatment (Figure 1). 
Antitumor efficacy
Seven patients were evaluable for response while four 
patients discontinued due to an FDA hold on pacritinib 
prior to first radiographic imaging. Of the 7 evaluable 
patients, 6 had disease progression while 1 had stable disease 
by RECIST criteria. No patient continued pacritinib for 
longer than 8 weeks.
Discussion
This study sought to demonstrate that inhibition of the 
JAK/STAT cytokine signaling pathway would lead to 
clinically meaningful responses in patients with refractory 
CRC. After eleven patients accrued and were initiated 
on treatment the Food and Drug Administration of the 
United States issued an order holding administration of 
pacritinib and halting clinical trial enrollment. This was 
based on emerging adverse safety data from the PERSIST-1 
trial in patients with myelofibrosis treated with pacritinib. 
During the clinical hold we determined that re-opening the 
study with additional safety parameters was not in the best 
interest of our patients given the lack of observed response 
to the investigational agent and uncertainty as to the safety 
of pacritinib. 
While we cannot evaluate the effect of pacritinib on 
our primary and secondary endpoints, several observations 
were made. The drug was only discontinued in one patient 
due to intolerance. There were no grade 4/5 events and no 
cardiovascular events were observed. The safety evaluation 
is limited by the short duration of treatment. Correlative 
analysis of inflammatory markers demonstrated an increase 
over the course of one month on treatment. Our opinion is 
Table 1 Characteristics of the eleven patients
Characteristic Value
Age, year
Median [range] 63 [43–80]
Female, no. [%] 7 [64]
Primary site, no. [%]
Right colon 7 [64]
Left colon 2 [18]
Rectum 2 [18]
RAS mutation, no. [%] 8 [73]
Baseline CRP, mg/L
Median [range] 12.1 [2.1–147]
Received adjuvant therapy, no. [%] 3 [27]
Prior lines of therapy for metastatic disease, no.
Median [range] 4 [2–6]






Clinical trial 5 [45]
Panitumumab 3 [27]
Xeloda 2 [18]
Table 2 Adverse events in 10 evaluable patients 
Event
No. of events [%]
Grade 1/2 Grade 3
Any adverse event 45 [100] 14 [50]
Nausea 5 [50] 1 [10]
Abdominal discomfort 4 [40] 0
Constipation 3 [30] 0
Fatigue 3 [30] 0
Mucositis 2 [20] 0
Peripheral edema 2 [20] 0
Diarrhea 1 [10] 0
Vomiting 1 [10] 0
Rash 1 [10] 0
Thrombocytopenia 0 1 [10]
Alkaline phosphatase increase 0 1 [10]
Serum bilirubin increase 0 1 [10]
Pleural effusion 0 1 [10]
Anemia 0 1 [10]
There were no grade 4/5 events reported. One patient was not 
included due to short duration on treatment.
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that this finding is most likely related to progressive disease 
but the possibility of an interaction with pacritinib should 
be explored further. We were unable to find published 
reports of CRP, IL-6 or IL-8 measurement in patients 
treated with pacritinib or other JAK inhibitors. 
The hypothesis that patients with high CRP levels would 
be more likely to respond to pacritinib was not supported 
by our observations. However, since no patient had an 
objective response to treatment this hypothesis cannot be 
evaluated.
The phase III  CORRECT tria l  of  regorafenib 
versus placebo found a small survival benefit in favor of 
regorafenib. Despite the modest difference, it supported 
a role for small-molecule multikinase inhibitors in the 
treatment of refractory colorectal cancer. Our median PFS 
expectation for pacritinib was deliberately set based on these 
results and pacritinib did not meet this endpoint. Further 
study of pacritinib as a single agent is not warranted based 
on our study, however; novel combinations with drugs 
targeting other molecular pathways could be explored. 
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Figure 1 Study participant serum concentrations for CRP and IL-6. Normalized serum concentrations of (A) CRP and (B) IL-6 at baseline 
and after one cycle of treatment with pacritinib. Each line represents an individual patient who had both the blood test at baseline and at the 
beginning of cycle 2. CRP, C-reactive protein. 
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